Elwan Alaa (Alaa Elwan)

Publication Activity (10 Years)

Years Active: 2021-2023
Publications (10 Years): 8

Top Topics

Tyrosine Kinase

Breast Cancer Cells

Vascular Endothelial Growth Factor

Top Venues

Journal of enzyme inhibition and medicinal chemistry

Molecules (Basel, Switzerland)

Future medicinal chemistry

This page only lists publications with an associated author ORCID identifier.

Publications

Hazem Elkady, Osama A El-Dardir, Elwan Alaa, Mohammed S Taghour, Hazem A Mahdy, Mohammed A Dahab, Eslam B Elkaeed, Bshra A Alsfouk, Ibrahim M Ibrahim, Dalal Z Husein, Elsayed E Hafez, Amira Muhammad Galal Darwish, Ahmed M Metwaly, Ibrahim H Eissa
Synthesis, biological evaluation and computer-aided discovery of new thiazolidine-2,4-dione derivatives as potential antitumor VEGFR-2 inhibitors. RSC advances 13 (40) (2023)
Hazem A Mahdy, Hazem Elkady, Mohammed S Taghour, Elwan Alaa, Mohammed A Dahab, Mohamed A Elkady, Elsayed Ge Elsakka, Eslam B Elkaeed, Bshra Ali A Alsfouk, Ibrahim M Ibrahim, Ibrahim H Eissa, Ahmed M Metwaly
New theobromine derivatives inhibiting VEGFR-2: design, synthesis, antiproliferative, docking and molecular dynamics simulations. Future medicinal chemistry (2023)
Eslam B Elkaeed, Ibrahim H Eissa, Hazem Elkady, Ahmed Abdelalim, Ahmad M Alqaisi, Aisha A Alsfouk, Elwan Alaa, Ahmed M Metwaly
A Multistage In Silico Study of Natural Potential Inhibitors Targeting SARS-CoV-2 Main Protease. International journal of molecular sciences 23 (15) (2022)
Elwan Alaa, Abdallah E Abdallah, Hazem A Mahdy, Mohammed A Dahab, Mohammed S Taghour, Eslam B Elkaeed, Ahmed B M Mehany, Ahmed Nabeeh, Mohammed Adel, Aisha A Alsfouk, Hazem Elkady, Ibrahim H Eissa
Modified Benzoxazole-Based VEGFR-2 Inhibitors and Apoptosis Inducers: Design, Synthesis, and Anti-Proliferative Evaluation. Molecules (Basel, Switzerland) 27 (15) (2022)
Reda G Yousef, Wagdy M Eldehna, Elwan Alaa, Abdelaziz S Abdelaziz, Ahmed B M Mehany, Ibraheem M M Gobaara, Bshra Ali A Alsfouk, Eslam B Elkaeed, Ahmed M Metwaly, Ibrahim H Eissa
Design, Synthesis, In Silico and In Vitro Studies of New Immunomodulatory Anticancer Nicotinamide Derivatives Targeting VEGFR-2. Molecules (Basel, Switzerland) 27 (13) (2022)
Elwan Alaa, Helmy Sakr, Abdel-Ghany A El-Helby, Ahmed El-Morsy, Mohamed Abdelwahab Abdelgawad, Mohammed M Ghoneim, Mohamed El-Sherbiny, Khaled El-Adl
Triazoloquinoxalines-based DNA intercalators-Topo II inhibitors: design, synthesis, docking, ADMET and anti-proliferative evaluations. Journal of enzyme inhibition and medicinal chemistry 37 (1) (2022)
Nawaf A Alsaif, Mohammed S Taghour, A F M Motiur Rahman, Ahmad J Obaidullah, Abdulrahman A Al-Mehizia, Manal M Alanazi, Saleh Aldawas, Elwan Alaa, Hazem Elkady
Discovery of new VEGFR-2 inhibitors based on bis([1, 2, 4]triazolo)[4,3-a:3',4'-c]quinoxaline derivatives as anticancer agents and apoptosis inducers. Journal of enzyme inhibition and medicinal chemistry 36 (1) (2021)
A F M Motiur Rahman, Elwan Alaa, Nawaf A Alsaif, Ahmad J Obaidullah, Hamad M Al Kahtani, Abdulrahman A Al-Mehizia, Sultan M Alsubaie, Mohammed S Taghour, Ibrahim H Eissa
Discovery of new 3-methylquinoxalines as potential anti-cancer agents and apoptosis inducers targeting VEGFR-2: design, synthesis, and in silico studies. Journal of enzyme inhibition and medicinal chemistry 36 (1) (2021)